nach oben

Erschienen in:

01.06.2019 | Current Opinion

Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

verfasst von: S. K. Haßel, G. Mayer

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Aptamers are synthetic DNA or RNA oligonucleotide ligands with great potential for therapeutic applications. A vast number of disease-related targets have been used to identify agonistic, antagonistic, or inhibitory aptamers, or aptamer-based targeting ligands. However, only a few aptamers have reached late-stage clinical trials so far and the commercial infrastructure is still far behind that of other therapeutic agents such as monoclonal antibodies. The desirable properties of aptamers such as selectivity, chemical flexibility, or cost-efficiency are faced by challenges, including a short half-life in vivo, immunogenicity, and entrapment in cellular organelles. Aptamer research is still in an early stage, and a deeper understanding of their structure, target interactions, and pharmacokinetics is necessary to catch up to the clinical market. In this review, we will discuss the benefits and limitations in the development of therapeutic aptamers, as well as the advances and future directions of aptamer research. The progress towards effective therapies seems to be slow, but it has not stopped and the best is yet to come.

Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science. 2000;287(5454):820–5.CrossRef

Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346(6287):818–22. https://doi.org/10.1038/346818a0.CrossRefPubMed

Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505–10.CrossRef

Gilboa E, McNamara J 2nd, Pastor F. Use of oligonucleotide aptamer ligands to modulate the function of immune receptors. Clin Cancer Res. 2013;19(5):1054–62. https://doi.org/10.1158/1078-0432.CCR-12-2067.CrossRefPubMed

Zhou J, Rossi JJ. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol Ther Nucleic Acids. 2014;3:e169. https://doi.org/10.1038/mtna.2014.21.CrossRefPubMedPubMedCentral

Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537–50. https://doi.org/10.1038/nrd3141.CrossRefPubMed

Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature. 1992;355(6360):564–6. https://doi.org/10.1038/355564a0.CrossRefPubMed

Kubik MF, Stephens AW, Schneider D, Marlar RA, Tasset D. High-affinity RNA ligands to human alpha-thrombin. Nucleic Acids Res. 1994;22(13):2619–26.CrossRef

Bompiani KM, Monroe DM, Church FC, Sullenger BA. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost. 2012;10(5):870–80. https://doi.org/10.1111/j.1538-7836.2012.04679.x.CrossRefPubMedPubMedCentral

10.

Tasset DM, Kubik MF, Steiner W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol. 1997;272(5):688–98. https://doi.org/10.1006/jmbi.1997.1275.CrossRefPubMed

11.

White R, Rusconi C, Scardino E, Wolberg A, Lawson J, Hoffman M, et al. Generation of species cross-reactive aptamers using “toggle” SELEX. Mol Ther. 2001;4(6):567–73. https://doi.org/10.1006/mthe.2001.0495.CrossRefPubMed

12.

Pagratis NC, Bell C, Chang YF, Jennings S, Fitzwater T, Jellinek D, et al. Potent 2’-amino-, and 2’-fluoro-2’-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat Biotechnol. 1997;15(1):68–73. https://doi.org/10.1038/nbt0197-68.CrossRefPubMed

13.

Binkley J, Allen P, Brown DM, Green L, Tuerk C, Gold L. RNA ligands to human nerve growth factor. Nucleic Acids Res. 1995;23(16):3198–205.CrossRef

14.

Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5(2):123–32. https://doi.org/10.1038/nrd1955.CrossRefPubMed

15.

Padilla R, Sousa R. Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2’-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res. 1999;27(6):1561–3.CrossRef

16.

Lee Y, Urban JH, Xu L, Sullenger BA, Lee J. 2’Fluoro modification differentially modulates the ability of RNAs to activate pattern recognition receptors. Nucleic Acid Ther. 2016;26(3):173–82. https://doi.org/10.1089/nat.2015.0575.CrossRefPubMedPubMedCentral

17.

Biesecker G, Dihel L, Enney K, Bendele RA. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology. 1999;42(1–3):219–30.CrossRef

18.

Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 2002;419(6902):90–4. https://doi.org/10.1038/nature00963.CrossRefPubMed

19.

Santulli-Marotto S, Nair SK, Rusconi C, Sullenger B, Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 2003;63(21):7483–9.PubMed

20.

Fülle L, Steiner N, Funke M, Gondorf F, Pfeiffer F, Siegl J, et al. RNA aptamers recognizing murine CCL17 Inhibit t cell chemotaxis and reduce contact hypersensitivity in vivo. Mol Ther. 2018;26(1):95–104. https://doi.org/10.1016/j.ymthe.2017.10.005.CrossRefPubMed

21.

Maier KE, Levy M. From selection hits to clinical leads: progress in aptamer discovery. Mol Ther Methods Clin Dev. 2016;5:16014. https://doi.org/10.1038/mtm.2016.14.CrossRefPubMedPubMedCentral

22.

Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, et al. Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun. 2018;9(1):1219. https://doi.org/10.1038/s41467-018-03631-z.CrossRefPubMedPubMedCentral

23.

Mi J, Liu Y, Rabbani ZN, Yang Z, Urban JH, Sullenger BA, et al. In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol. 2010;6(1):22–4. https://doi.org/10.1038/nchembio.277.CrossRefPubMed

24.

Pereira RL, Nascimento IC, Santos AP, Ogusuku IEY, Lameu C, Mayer G, et al. Aptamers: novelty tools for cancer biology. Oncotarget. 2018;9(42):26934–53. https://doi.org/10.18632/oncotarget.25260.CrossRefPubMedPubMedCentral

25.

McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Investig. 2008;118(1):376–86. https://doi.org/10.1172/JCI33365.CrossRefPubMed

26.

Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariepy J. Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers. Mol Ther Nucleic Acids. 2015;4:e237. https://doi.org/10.1038/mtna.2015.11.CrossRefPubMedPubMedCentral

27.

Lai WY, Huang BT, Wang JW, Lin PY, Yang PC. A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects. Mol Ther Nucleic Acids. 2016;5(12):e397. https://doi.org/10.1038/mtna.2016.102.CrossRefPubMed

28.

Wang H, Lam CH, Li X, West DL, Yang X. Selection of PD1/PD-L1 X-aptamers. Biochimie. 2018;145:125–30. https://doi.org/10.1016/j.biochi.2017.09.006.CrossRefPubMed

29.

Huang BT, Lai WY, Chang YC, Wang JW, Yeh SD, Lin EP, et al. A CTLA-4 antagonizing DNA aptamer with antitumor effect. Mol Ther Nucleic Acids. 2017;8:520–8. https://doi.org/10.1016/j.omtn.2017.08.006.CrossRefPubMedPubMedCentral

30.

Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002;62(14):4029–33.PubMed

31.

Cerchia L, Esposito CL, Camorani S, Rienzo A, Stasio L, Insabato L, et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther. 2012;20(12):2291–303. https://doi.org/10.1038/mt.2012.163.CrossRefPubMedPubMedCentral

32.

Lupold SE. Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey. Am J Clin Exp Urol. 2018;6(2):78–86.PubMedPubMedCentral

33.

Esposito CL, Cerchia L, Catuogno S, De Vita G, Dassie JP, Santamaria G, et al. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther. 2014;22(6):1151–63. https://doi.org/10.1038/mt.2014.5.CrossRefPubMedPubMedCentral

34.

Iaboni M, Russo V, Fontanella R, Roscigno G, Fiore D, Donnarumma E, et al. Aptamer-miRNA-212 conjugate sensitizes NSCLC cells to TRAIL. Mol Ther Nucleic Acids. 2016;5:e289. https://doi.org/10.1038/mtna.2016.5.CrossRefPubMedPubMedCentral

35.

Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F, et al. Aptamer-miR-34c conjugate affects cell proliferation of non-small-cell lung cancer cells. Mol Ther Nucleic Acids. 2018;13:334–46. https://doi.org/10.1016/j.omtn.2018.09.016.CrossRefPubMedPubMedCentral

36.

Esposito CL, Nuzzo S, Kumar SA, Rienzo A, Lawrence CL, Pallini R, et al. A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells. J Control Release. 2016;238:43–57. https://doi.org/10.1016/j.jconrel.2016.07.032.CrossRefPubMed

37.

Green LS, Jellinek D, Jenison R, Ostman A, Heldin CH, Janjic N. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry. 1996;35(45):14413–24. https://doi.org/10.1021/bi961544+.CrossRefPubMed

38.

Dunn EN, Hariprasad SM, Sheth VS. An overview of the Fovista and Rinucumab trials and the fate of anti-PDGF medications. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):100–4. https://doi.org/10.3928/23258160-20170130-02.CrossRefPubMed

39.

Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation. 2010;122(6):614–22. https://doi.org/10.1161/CIRCULATIONAHA.109.927756.CrossRefPubMed

40.

Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol. 2016;137(5):1610 e7–1613 e7. https://doi.org/10.1016/j.jaci.2015.10.034.CrossRef

41.

Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328–35. https://doi.org/10.1016/j.bbrc.2005.05.132.CrossRefPubMed

42.

Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85(4):425–30. https://doi.org/10.1016/j.exer.2007.05.008.CrossRefPubMed

43.

Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther. 2013;7:711–22. https://doi.org/10.2147/DDDT.S40215.CrossRefPubMedPubMedCentral

44.

D’Amore PA. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol. 2007;171(1):14–8. https://doi.org/10.2353/ajpath.2007.070385.CrossRefPubMedPubMedCentral

45.

Drolet DW, Green LS, Gold L, Janjic N. Fit for the eye: aptamers in ocular disorders. Nucleic Acid Ther. 2016;26(3):127–46. https://doi.org/10.1089/nat.2015.0573.CrossRefPubMedPubMedCentral

46.

Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9–14. https://doi.org/10.4161/19420862.2015.989042.CrossRefPubMed

47.

Hernandez FJ, Kalra N, Wengel J, Vester B. Aptamers as a model for functional evaluation of LNA and 2’-amino LNA. Bioorg Med Chem Lett. 2009;19(23):6585–7. https://doi.org/10.1016/j.bmcl.2009.10.039.CrossRefPubMed

48.

Pinheiro VB, Taylor AI, Cozens C, Abramov M, Renders M, Zhang S, et al. Synthetic genetic polymers capable of heredity and evolution. Science. 2012;336(6079):341–4. https://doi.org/10.1126/science.1217622.CrossRefPubMedPubMedCentral

49.

Green LS, Jellinek D, Bell C, Beebe LA, Feistner BD, Gill SC, et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol. 1995;2(10):683–95.CrossRef

50.

Dass CR, Saravolac EG, Li Y, Sun LQ. Cellular uptake, distribution, and stability of 10–23 deoxyribozymes. Antisense Nucleic Acid Drug Dev. 2002;12(5):289–99. https://doi.org/10.1089/108729002761381276.CrossRefPubMed

51.

Lauridsen LH, Rothnagel JA, Veedu RN. Enzymatic recognition of 2’-modified ribonucleoside 5’-triphosphates: towards the evolution of versatile aptamers. Chembiochem. 2012;13(1):19–25. https://doi.org/10.1002/cbic.201100648.CrossRefPubMed

52.

Loakes D, Holliger P. Polymerase engineering: towards the encoded synthesis of unnatural biopolymers. Chem Commun (Camb). 2009;31:4619–31. https://doi.org/10.1039/b903307f.CrossRef

53.

Meyer AJ, Garry DJ, Hall B, Byrom MM, McDonald HG, Yang X, et al. Transcription yield of fully 2’-modified RNA can be increased by the addition of thermostabilizing mutations to T7 RNA polymerase mutants. Nucleic Acids Res. 2015;43(15):7480–8. https://doi.org/10.1093/nar/gkv734.CrossRefPubMedPubMedCentral

54.

Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer((R)) therapeutics. Drug Discov Today. 2015;20(1):147–55. https://doi.org/10.1016/j.drudis.2014.09.004.CrossRefPubMed

55.

Nolte A, Klussmann S, Bald R, Erdmann VA, Furste JP. Mirror-design of l-oligonucleotide ligands binding to l-arginine. Nat Biotechnol. 1996;14(9):1116–9. https://doi.org/10.1038/nbt0996-1116.CrossRefPubMed

56.

Klussmann S, Nolte A, Bald R, Erdmann VA, Furste JP. Mirror-image RNA that binds d-adenosine. Nat Biotechnol. 1996;14(9):1112–5. https://doi.org/10.1038/nbt0996-1112.CrossRefPubMed

57.

Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 2014;123(7):1032–9. https://doi.org/10.1182/blood-2013-03-493924.CrossRefPubMedPubMedCentral

58.

Ninichuk V, Clauss S, Kulkarni O, Schmid H, Segerer S, Radomska E, et al. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3’PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol. 2008;172(3):628–37. https://doi.org/10.2353/ajpath.2008.070601.CrossRefPubMedPubMedCentral

59.

Schwoebel F, van Eijk LT, Zboralski D, Sell S, Buchner K, Maasch C, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013;121(12):2311–5. https://doi.org/10.1182/blood-2012-09-456756.CrossRefPubMedPubMedCentral

60.

Healy JM, Lewis SD, Kurz M, Boomer RM, Thompson KM, Wilson C, et al. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res. 2004;21(12):2234–46.CrossRef

61.

Lee CH, Lee SH, Kim JH, Noh YH, Noh GJ, Lee SW. Pharmacokinetics of a cholesterol-conjugated aptamer against the hepatitis C virus (HCV) NS5B protein. Mol Ther Nucleic Acids. 2015;4:e254. https://doi.org/10.1038/mtna.2015.30.CrossRefPubMedPubMedCentral

62.

Zhang P, Sun F, Liu S, Jiang S. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J Control Release. 2016;244(Pt B):184–93. https://doi.org/10.1016/j.jconrel.2016.06.040.CrossRefPubMedPubMedCentral

63.

Bruno JG. Potential inherent stimulation of the innate immune system by nucleic acid aptamers and possible corrective approaches. Pharmaceuticals (Basel). 2018. https://doi.org/10.3390/ph11030062.CrossRefPubMedPubMedCentral

64.

Civit L, Taghdisi SM, Jonczyk A, Hassel SK, Grober C, Blank M, et al. Systematic evaluation of cell-SELEX enriched aptamers binding to breast cancer cells. Biochimie. 2018;145:53–62. https://doi.org/10.1016/j.biochi.2017.10.007.CrossRefPubMed

65.

Avci-Adali M, Steinle H, Michel T, Schlensak C, Wendel HP. Potential capacity of aptamers to trigger immune activation in human blood. PLoS One. 2013;8(7):e68810. https://doi.org/10.1371/journal.pone.0068810.CrossRefPubMedPubMedCentral

66.

D’Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113(6):992 e6–1001 e6. https://doi.org/10.1016/j.ophtha.2006.02.027.CrossRef

67.

Farman CA, Kornbrust DJ. Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicol Pathol. 2003;31(Suppl):119–22. https://doi.org/10.1080/01926230390174995.CrossRefPubMed

68.

Goebl N, Berridge B, Wroblewski VJ, Brown-Augsburger PL. Development of a sensitive and specific in situ hybridization technique for the cellular localization of antisense oligodeoxynucleotide drugs in tissue sections. Toxicol Pathol. 2007;35(4):541–8. https://doi.org/10.1080/01926230701338958.CrossRefPubMed

69.

Henry SP, Zuckerman JE, Rojko J, Hall WC, Harman RJ, Kitchen D, et al. Toxicological properties of several novel oligonucleotide analogs in mice. Anticancer Drug Des. 1997;12(1):1–14.PubMed

70.

Paul A, Avci-Adali M, Neumann B, Guo K, Straub A, Dietz K, et al. Aptamers influence the hemostatic system by activating the intrinsic coagulation pathway in an in vitro Chandler-Loop model. Clin Appl Thromb Hemost. 2010;16(2):161–9. https://doi.org/10.1177/1076029608329580.CrossRefPubMed

71.

Gansler J, Jaax M, Leiting S, Appel B, Greinacher A, Fischer S, et al. Structural requirements for the procoagulant activity of nucleic acids. PLoS One. 2012;7(11):e50399. https://doi.org/10.1371/journal.pone.0050399.CrossRefPubMedPubMedCentral

72.

Perschbacher K, Smestad JA, Peters JP, Standiford MM, Denic A, Wootla B, et al. Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice. Nucleic Acid Ther. 2015;25(1):11–9. https://doi.org/10.1089/nat.2014.0515.CrossRefPubMedPubMedCentral

73.

Thiel WH, Thiel KW, Flenker KS, Bair T, Dupuy AJ, McNamara JO 2nd, et al. Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells. Methods Mol Biol. 2015;1218:187–99. https://doi.org/10.1007/978-1-4939-1538-5_11.CrossRefPubMedPubMedCentral

74.

Yan A, Levy M. Cell internalization SELEX: in vitro selection for molecules that internalize into cells. Methods Mol Biol. 2014;1103:241–65. https://doi.org/10.1007/978-1-62703-730-3_18.CrossRefPubMed

75.

Tawiah KD, Porciani D, Burke DH. Toward the selection of cell targeting aptamers with extended biological functionalities to facilitate endosomal escape of cargoes. Biomedicines. 2017. https://doi.org/10.3390/biomedicines5030051.CrossRefPubMedPubMedCentral

76.

Mayer G, Pofahl M, Schöler KMU, Haßel S. Cell-specific aptamers for nano-medical applications. In: Kjems J, Ferapontova E, Gothelf K, editors. Nucleic acid nanotechnology. Berlin: Springer; 2014.

77.

Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35(3):222–9. https://doi.org/10.1038/nbt.3802.CrossRefPubMed

78.

Liu HY, Gao X. A universal protein tag for delivery of SiRNA-aptamer chimeras. Sci Rep. 2013;3:3129. https://doi.org/10.1038/srep03129.CrossRefPubMedPubMedCentral

79.

Nossal GJ, Lederberg J. Antibody production by single cells. Nature. 1958;181(4620):1419–20.CrossRef

80.

Ribatti D. Edelman’s view on the discovery of antibodies. Immunol Lett. 2015;164(2):72–5. https://doi.org/10.1016/j.imlet.2015.02.005.CrossRefPubMed

81.

Hey A. History and practice: antibodies in infectious diseases. Microbiol Spectr. 2015;3(2):AID-0026-2014. https://doi.org/10.1128/microbiolspec.aid-0026-2014.CrossRefPubMed

82.

Llewelyn MB, Hawkins RE, Russell SJ. Discovery of antibodies. BMJ. 1992;305(6864):1269–72.CrossRef

83.

Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.CrossRef

84.

Tonegawa S. Somatic generation of antibody diversity. Nature. 1983;302(5909):575–81.CrossRef

85.

Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12(5):615–22. https://doi.org/10.1016/j.coph.2012.08.001.CrossRefPubMed

86.

Robertson DL, Joyce GF. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature. 1990;344(6265):467–8. https://doi.org/10.1038/344467a0.CrossRefPubMed

87.

Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009;86(3):151–64. https://doi.org/10.1016/j.yexmp.2009.01.004.CrossRefPubMedPubMedCentral

88.

Mongelard F, Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther. 2010;12(1):107–14.PubMed

89.

Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010;70(21):8617–29. https://doi.org/10.1158/0008-5472.CAN-10-0920.CrossRefPubMedPubMedCentral

90.

Baker M. Reproducibility crisis: blame it on the antibodies. Nature. 2015;521(7552):274–6. https://doi.org/10.1038/521274a.CrossRefPubMed

91.

Bradbury A, Pluckthun A. Reproducibility: standardize antibodies used in research. Nature. 2015;518(7537):27–9. https://doi.org/10.1038/518027a.CrossRefPubMed

92.

Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol Ther. 2017;25(5):1069–75. https://doi.org/10.1016/j.ymthe.2017.03.023.CrossRefPubMedPubMedCentral

93.

Smith CIE, Zain R. Therapeutic oligonucleotides: state of the art. Annu Rev Pharmacol Toxicol. 2019;59:605–30. https://doi.org/10.1146/annurev-pharmtox-010818-021050.CrossRefPubMed

94.

Diener JL, Daniel Lagasse HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R, et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost. 2009;7(7):1155–62. https://doi.org/10.1111/j.1538-7836.2009.03459.x.CrossRefPubMed

95.

Troisi R, Napolitano V, Spiridonova V, Russo Krauss I, Sica F. Several structural motifs cooperate in determining the highly effective anti-thrombin activity of NU172 aptamer. Nucleic Acids Res. 2018;46(22):12177–85. https://doi.org/10.1093/nar/gky990.CrossRefPubMedPubMedCentral

96.

Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood. 2011;117(20):5514–22. https://doi.org/10.1182/blood-2010-10-311936.CrossRefPubMed

97.

Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol. 2007;18(8):2350–8. https://doi.org/10.1681/ASN.2006121348.CrossRefPubMed

Titel: Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?
verfasst von: S. K. Haßel
G. Mayer
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Molecular Diagnosis & Therapy / Ausgabe 3/2019
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI: https://doi.org/10.1007/s40291-019-00400-6

Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis

Original Research Article

Advances in Detection of Kidney Transplant Injury

Review Article

Mutational Landscape of Resistance to Thyroid Hormone Beta (RTHβ)

Review Article

Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis

Original Research Article

Vortex- and Centrifugation-Free Extraction of HIV-1 RNA

Original Research Article

Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)

Review Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

17.01.2025
Dekubitus
Nachrichten

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

17.01.2025
Kolorektales Karzinom
Nachrichten

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

16.01.2025
Primäre Glomerulonephritiden
Nachrichten

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Abstract

Weitere Artikel der Ausgabe 3/2019

Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis

Advances in Detection of Kidney Transplant Injury

Mutational Landscape of Resistance to Thyroid Hormone Beta (RTHβ)

Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis

Vortex- and Centrifugation-Free Extraction of HIV-1 RNA

Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Schützt das tägliche Glas Milch vor Darmkrebs?

Vorsicht mit Glukokortikoiden bei Glomerulopathie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten